

Reaction of (13*S*)-13-iodo-6β-methoxy-3α,5-cyclo-13,14-seco-5α-androstane-14,17-dione with hydroxylamine and its application to the synthesis of new 13,14-seco steroids

Vladimir A. Khripach^{a,*}, Vladimir N. Zhabinskii^a, Anna I. Kuchto^a, Galina P. Fando^a, Yuliya Y. Zhiburtovich^a, Alexander S. Lyakhov^a, Alla A. Govorova^a, Marinus B. Groen^b, Jaap van der Louw^b, Aede de Groot^c

^a Institute of Bioorganic Chemistry, National Academy of Sciences of Belarus, Kuprevich str., 5/2, 220141 Minsk, Belarus

^b Department of Medicinal Chemistry, N.V. Organon, P.O. Box 20, 5340 BH Oss, The Netherlands

^c Laboratory of Organic Chemistry, Wageningen University, Dreijenplein 8, 6703 HB Wageningen, The Netherlands

Received 9 December 2003; received in revised form 20 April 2004; accepted 27 April 2004

Available online 19 June 2004

Abstract

The synthesis of 13,14-seco steroids starting from easily available (13*S*)-13-iodo-6β-methoxy-3α,5-cyclo-13,14-seco-5α-androsta-14,17-dione is described. The C-17 ketone was converted regioselectively into its oxime with simultaneous stereoselective deiodination at C-13. The remaining C-14 carbonyl group was then reduced stereoselectively with Ca(BH₄)₂. The configurations at the relevant stereocenters of the thus obtained hydroxy oxime were determined by X-ray analysis. Successful regeneration of the C-17 carbonyl group was achieved by treatment of the corresponding oxime acetate with TiCl₃.

© 2004 Elsevier Inc. All rights reserved.

Keywords: Seco steroids; Reduction; Oximes; Fragmentation

1. Introduction

Studies on 5,10-seco steroids have shown that modification of the rigid tetracyclic steroidal carbon skeleton by cleavage of an internal C–C bond provides more flexible compounds with new biological properties [1–6]. Radical oxidation of C-5 alcohols has been the most studied process for the preparation of 5,10-seco steroids [7–11], but only a few articles have been published on the radical oxidation of C-14 alcohols for synthesis of 13,14-seco steroids [12–14]. Comparison of the biological properties of such compounds with those of the tetracyclic natural steroids is of great interest and is stimulated further by the occurrence of 13,14-seco steroids in nature [15–17].

Earlier, we reported on the radical oxidation of 17-functionalized 14α-hydroxy steroids [14], and the stereochemistry at C-13 was established (Scheme 1). The yield of this reaction was improved up to 85%, which made it an


attractive route for preparation of a variety of 13,14-seco steroids. As compound **2** contains keto groups at C-14 and C-17, one of them has to be differentiated from the other to allow further synthetic manipulations and to prevent easy recyclization. An additional problem is the deiodination step, which may be accompanied by a change of stereochemistry at C-13.

We now report a synthetic route to 13,14-seco steroids with different functional groups at C-14 and C-17 using oximation with simultaneous dehalogenation of **2**. The stereochemistry of one of the reaction products was determined by X-ray.

2. Experimental

Melting points were taken on a Boetius micro-melting point apparatus and are uncorrected. IR spectra were recorded on a UR-20 spectrophotometer in KBr tablets. ¹H and ¹³C NMR spectra were taken on a Bruker AC-200 (200 MHz for ¹H, 50 MHz for ¹³C) spectrometer using

* Corresponding author. Tel.: +375 2 648 647; fax: +375 2 648 647.
E-mail address: khripach@iboch.bas-net.by (V.A. Khripach).



Scheme 1.

TMS as an internal standard in CDCl_3 , and chemical shifts are given in δ (ppm). Exact mass was determined by ESI-TOF analysis performed on a Perkin Elmer Q-STAR XL TOF spectrometer. X-ray data collection (Nicolet R3m diffractometer) was performed via the $\omega/2\theta$ scan mode. The structure was solved by direct methods (SIR97) [18] and refined by full-matrix least squares (SHELXL 97) [19]. Positions of hydrogen atoms were calculated and refined by using the riding model [19]. All chemicals were of analytical grade. Reactions were monitored by TLC using aluminium or plastic sheets, silica gel 60 F₂₅₄ precoated (Merck Art. 5715). Column chromatography was carried out on Kieselgel 60 (Merck Art. 7734).

2.1. Radical dehalogenation of (2)

AIBN (1 mg, 0.006 mmol) and Bu_3SnH (0.4 ml, 1.50 mmol) were added to a solution of (13*S*)-13-iodo-6 β -methoxy-3 α ,5-cyclo-13,14-*seco*-5 α -androstan-14,17-dione **2** (100 mg, 0.23 mmol, prepared according to [14]) in dry benzene (5 ml), and the reaction mixture was refluxed for 30 min. Then, the solvent was evaporated, and the residue was dissolved in MeCN (5 ml) and washed three times with pentane. The solvents were evaporated, and the remaining oil was purified on SiO_2 (EtOAc:petroleum ether, 1:1) to give: (i) inseparable mixture of C-13 epimers of 6 β -methoxy-3 α ,5-cyclo-13,14-*seco*-5 α -androstan-14,17-dione **3** (50 mg, 70%) as an oil. IR (cm^{-1}): 1715, 1470, 1450, 1380, 1330, 1090. ^1H NMR δ : 0.45–0.55 (m, 1H, 4-H), 0.63–0.71 (m, 1H, 4H), 1.03 (s, 3H, 18-H), 0.98–1.02 (m, 6H, 18- and 19-H), 2.93 (m, 1H, 6-H), 3.31 (s, 2/3H, OMe), 3.32 (s, 1/3H, OMe); (ii) 6 β -methoxy-14 β -hydroxy-3 α ,5-cyclo-5 α -androstan-17-one **4** (10 mg, 14%) as an oil. IR (cm^{-1}): 1745, 1460, 1380, 1290, 1100, 965. ^1H NMR δ : 0.45–0.60 (m, 1H, 4-H), 0.65–0.80 (m, 1H, 4H), 1.03 (s, 3H, 18-H), 1.09 (s, 3H, 19-H), 2.91 (m, 1H, 6-H), 3.36 (s, 3H, OMe). ^{13}C NMR δ : 13.0, 13.4, 19.1, 21.4, 21.5, 24.9, 26.7, 29.4, 32.2, 33.1, 33.6, 34.7, 36.6, 43.7, 44.0, 53.8, 56.6, 82.0, 82.2, 221.6.

2.2. (13*S*)-6 β -Methoxy-3 α ,5-cyclo-13,14-*seco*-5 α -androstan-14,17-dione 17-oxime (**5**)

$\text{NH}_2\text{OH}\cdot\text{HCl}$ (470 mg, 6.8 mmol) was added to a solution of diketone **2** (1.0 g, 2.25 mmol) in pyridine (20 ml). The obtained solution was kept at room temperature for 24 h, then

diluted with water, and extracted with CHCl_3 . The solvents were evaporated, and the residue was chromatographed on SiO_2 (EtOAc:petroleum ether, 1:2) to give oxime **5** (490 mg, 65%). Mp 190–192 °C (hexane–EtOAc). IR (cm^{-1}): 1710, 1450, 1385, 1110, 1090. ^1H NMR δ : 0.42–0.56 (m, 1H, 4-H), 0.64–0.72 (m, 1H, 4-H), 0.98 (d, 1H, $J = 7$ Hz, 18-H), 1.02 (s, 3H, 19-H), 2.81 (m, 1H, 6-H), 3.31 (s, 3H, OMe). ^{13}C NMR δ : 13.0, 18.5, 18.7, 20.3, 21.3, 21.4, 24.6, 24.8, 26.4, 32.8, 33.0, 34.3, 39.3, 41.7, 45.3, 48.6, 48.9, 56.7, 81.5, 165.8, 220.4.

2.3. (13*S*,14*S*)-14-Hydroxy-6 β -methoxy-3 α ,5-cyclo-13,14-*seco*-5 α -androstan-17-one 17-oxime (**6**)

NaBH_4 (23.9 mg, 0.63 mmol) in water (0.1 ml) was added to a solution of ketoxime **5** (70 mg, 0.21 mmol) and CaCl_2 (69.9 mg, 0.63 mmol) in 95% ethanol (3 ml). After 5 min, the reaction mixture was diluted with water and extracted with EtOAc and CHCl_3 . The organic layers were dried and evaporated. The residue was chromatographed on SiO_2 (hexane:EtOAc, 1:1) to give alcohol **6** (40 mg, 57%) as white crystals. Mp 189–192 °C (hexane–EtOAc). ^1H NMR δ : 0.40–0.52 (m, 1H, 4-H), 0.62–0.68 (m, 1H, 4-H), 0.98 (s, 3H, 19-H), 1.10 (d, 3H, $J = 7$ Hz, 18-H), 2.85 (m, 1H, 6-H), 3.32 (s, 3H, OMe), 4.21 (m, 1H, 14-H). ^{13}C NMR δ : 12.9, 17.9, 18.5, 21.7, 24.8, 25.4, 28.3, 29.1, 33.8, 34.5, 35.5, 35.9, 39.9, 39.9, 43.5, 46.6, 56.5, 71.7, 82.4, 165.5.

2.4. (13*S*,14*S*)-14,17-Diacetoxy-6 β -methoxy-3 α ,5-cyclo-13,14-*seco*-5 α -androstan-17-one 17-oxime (**7**)

A solution of hydroxy oxime **6** (500 mg, 1.49 mmol) and Ac_2O (1.0 ml, 6.75 mmol) in pyridine (5 ml) was left at room temperature for 16 h. Then, it was diluted with water, and extracted with CHCl_3 , and the solvents were evaporated. The residue was chromatographed on SiO_2 (hexane:EtOAc, 1:2) to give diacetate **7** (500 mg, 85%). Mp 123–125 °C (hexane:EtOAc). IR (cm^{-1}): 1780, 1740, 1640, 1480, 1470, 1380, 1270, 1080. ^1H NMR δ : 0.36–0.46 (m, 1H, 4-H), 0.60–0.66 (m, 1H, 4-H), 0.94 (s, 3H, 19-H), 1.22 (d, $J = 7$ Hz, 3H, 18-H), 2.04 (s, 3H, OAc), 2.20 (s, 3H, OAc), 2.80 (m, 1H, 6-H), 3.26 (s, 3H, OMe), 5.32 (m, 1H, 14-H). ^{13}C NMR δ : 12.9, 16.7, 18.4, 19.8, 21.5, 21.8, 24.6, 26.4, 27.7, 28.2, 32.7, 33.5, 35.5, 37.2, 40.2, 46.4, 56.2, 75.1, 81.8, 169.3, 170.4, 173.5.

2.5. (13*S*,14*S*)-14-Acetoxy-6 β -methoxy-3 α ,5-cyclo-13,14-*seco*-5 α -androstan-17-one (**8**)

A solution of KOAc (2.76 g, 28 mmol) in water (0.5 ml) was added to a stirred solution of diacetate **7** (110 mg, 0.28 mmol) in acetone (5 ml). This was followed by treatment with a 15% solution of TiCl_3 in water (2.80 ml, 2.80 mmol). The mixture was stirred for 2 h, then filtered,

diluted with water, and extracted with EtOAc and Et₂O. The combined extracts were dried (Na₂SO₄) and evaporated, and the residue was chromatographed on silica gel (hexane:EtOAc, 3:1) to give the acetoxy ketone **8** (50 mg, 52%) as an oil. IR (cm⁻¹): 1740, 1715, 1460, 1380, 1255, 1100, 1030. ¹H NMR δ: 0.38–0.46 (m, 1H, 4-H), 0.60–0.68 (m, 1H, 4-H), 0.94 (s, 3H, 19-H), 1.06 (d, *J* = 7 Hz, 3H, 18-H), 2.04 (s, 3H, OAc), 2.81 (m, 1H, 6-H), 3.28 (s, 3H, OMe), 5.38 (d, *J* = 7 Hz, 1H, 14-H). ¹³C NMR δ: 12.9, 14.8, 18.5, 21.5, 21.8, 24.7, 27.1, 28.9, 32.1, 33.5, 35.4, 37.2, 39.2, 39.7, 46.4, 47.5, 56.2, 75.4, 81.7, 170.7, 218.7. HRMS calculated for C₂₂H₃₅O₄ [M+H]⁺: 363.2535; found: 363.2516.

3. Results and discussion

Our first experiments with iodo diketone **2** showed that this compound was prone to an easy loss of iodine, followed by an aldol reaction of the intermediate **3** to give the 14β-alcohol **4** (Scheme 2). Earlier, this sequence was suggested for 14α-hydroxy-17-ketones as a convenient method to invert the stereochemistry at C-14 [12]. The reduction of **2** with various reagents, its treatment with base, and its attempts to protect the carbonyl group(s), all led to formation of hydroxy ketone **4**. Only radical dehalogenation with Bu₃SnH resulted in diketone **3** in a good yield (70%) together with the cyclization product **4** (14%). However, isomerization at C-13 accompanied the dehalogenation, which made the synthetic value of this reaction doubtful.

A good result was achieved by treatment of iodo ketone **2** with hydroxylamine. The reaction led to oximation of the 17-keto group with simultaneous deiodination at C-13 to give **5** in 65% yield. Hydride reduction of **5** gave alcohol **6**. It is worth mentioning that both transformations were stereoselective. The unambiguous assignment of the stereochemistry at C-13 and C-14 in **6** was provided by a single-crystal X-ray diffraction study, which showed that the reductive





Fig. 1. ORTEP [22] view of (13*S*,14*S*)-14-hydroxy-6β-methoxy-3α,5-cyclo-13,14-seco-5α-androstan-17-one 17-oxime **6**. Displacement ellipsoids are drawn at 40% probability level.

deiodination of **2** with NH₂OH had proceeded with inversion of the configuration at C-13 (Fig. 1, Table 1).

Treatment of oximes with trivalent titanium is often used to transform these compounds into their parent ketones [20]. However, in our case, the reaction of **6** with TiCl₃ led to the formation of unidentified products. The use of oxime *O*-acetates has been described for the transformation of sensitive ketoximes into ketones [21]. Acetylation of hydroxy oxime **6** gave the diacetate **7** (Scheme 2), and treatment of this compound with TiCl₃ indeed led to the desired acetoxy ketone **8**.

In summary, a new synthesis of 13,14-seco steroids has been developed via the acetoxy ketone **8**. In this compound, the keto group at C-17 and the acetoxy group at C-14 can be modified independently, thus allowing for various transformations into a variety of substituted 13,14-seco steroids.



Scheme 2.

Table 1

Crystal data and structure refinement for (13*S*,14*S*)-14-hydroxy-6 β -methoxy-3 α ,5-cyclo-13,14-seco-5 α -androstan-17-one 17-oxime **6**

Empirical formula	C ₂₀ H ₃₃ NO ₃
Formula weight	335.47
Temperature	293(2)K
Wavelength	0.71069 Å
Crystal system	Orthorhombic
Space group	P2 ₁ 2 ₁ 2 ₁
Unit cell dimensions	$a = 7.669(1)$ Å; $\alpha = 90^\circ$ $b = 9.015(1)$ Å; $\beta = 90^\circ$ $c = 26.536(4)$ Å; $\gamma = 90^\circ$
Volume	1834.6(4) Å ³
Z	4
Density (calculated)	1.215 mg m ⁻³
Absorption coefficient	0.080 mm ⁻¹
$F(000)$	736
Crystal size	0.62 × 0.52 × 0.34 mm ³
Theta range for data collection	1.53–30.06°.
Index ranges	0 ≤ h ≤ 10, 0 ≤ k ≤ 12, −1 ≤ l ≤ 37
Reflections collected	3191
Independent reflections	3169 [$R(\text{int}) = 0.0091$]
Completeness to theta = 30.06°	100.0%
Absorption correction	None
Refinement method	Full-matrix least-squares on F^2
Data/restraints/parameters	3169/0/222
Goodness-of-fit on F^2	1.046
Final R indices ($I > 2\sigma(I)$)	$R1 = 0.0367$, $wR2 = 0.0975$
R indices (all data)	$R1 = 0.0437$, $wR2 = 0.1033$
Largest diff. peak and hole	0.160 and −0.145 e.Å ⁻³

Acknowledgements

The authors are indebted to Organon International for financial support of this research. We thank Dr. N.B. Khripach and E.V. Skorodumov for recording NMR spectra and Mr. E. van Beelen and Ms. J. Verhoosel for the exact mass measurements.

References

- [1] Batzold FH, Robinson CH. Synthesis of β,γ -acetylenic 3-oxo steroids of the 5,10-seco series. *J Org Chem* 1976;41:313–7.
- [2] Smith AG, Brooks CJW. The substrate specificity and stereochemistry, reversibility and inhibition of the 3-oxo steroid Δ^4 - Δ^5 -isomerase component of cholesterol oxidase. *Biochem J* 1977; 167:121–9.
- [3] Zerhouni NA, Maes M, Sultan C, Rothwell S, Migeon CJ. Selective inhibition by secosteroids of 5 α -reductase activity in human sex skin fibroblasts. *Steroids* 1979;33:277–85.
- [4] Penning TM, Covey DF, Talalay P. Irreversible inactivation of Δ^5 -3-ketosteroid isomerase of *Pseudomonas testosterone* by acetylenic suicide substrates. *J Biol Chem* 1981;256:6842–50.
- [5] Penning TM. Inactivation of Δ^5 -3-ketosteroid isomerase(s) from beef adrenal cortex by β,γ -acetylenic ketosteroids. *Steroids* 1982;39:301–11.
- [6] Vazquez MH, Tezon JG, Blaquier JA. Studies on the mechanism of the antiandrogenic effect of a putative 5 α -reductase inhibitor. *J Steroid Biochem* 1987;28:227–31.
- [7] Rosenthal D, Lefler CF, Wall ME. The lead tetraacetate oxidation of a 5-hydroxy-B-norsteroid. *Tetrahedron* 1967;23:3583–600.
- [8] Fuhrer H, Lorenc L, Pavlović V, Rihs G, Rist G, Kalvoda J, et al. (*E*)-3 α -Acetoxy-5,10-seco-l(10)-cholesten-5-one and (*E*)-5,10-seco-l(10)-cholestene-3,5-dione. *Helv Chim Acta* 1979;62:1770–84.
- [9] Balasubramanian V, Robinson CH. Oxidative cyclization and fragmentation of steroidal alcohols induced by ceric ammonium nitrate. *Tetrahedron Lett* 1981;22:501–4.
- [10] Lorenc L, Rajković M, Milovanović A, Mihailović ML. Structure–reactivity relationships in normal and 19-nor-5,10-seco-steroidal cyclodecenone systems. Part 1. Acid-catalysed and thermal reactions. *J Chem Soc Perkin Trans* 1988;(I):1495–8.
- [11] Mihailović ML, Raiković MM, Lorenc LB, Pavlović VD, Milovanović AZ, Tinant B, Declercq JP. Structure and reactivity in 19-Me and 19-nor-5,10-secosteroids. *Tetrahedron* 1996;52:11995–2008.
- [12] Anner G, Kalvoda J., Inventors; Ciba Corp., Switzerland, Assignee. 13,14-Seco-steroids and process for preparation thereof. USA 3,470,240; [CA, 1966, 65, 775A].
- [13] Bjelaković MS, Lorenc LB, Pavlović VD, Michailović ML, Tinant B, Declercq JP, et al. 13,14-Seco steroids: a new type of modified steroids containing a nine-membered ring. *Helv Chim Acta* 1999;82:707–21.
- [14] Khripach VA, Zhabinskii VN, Kotyatkina AI, Fando GP, Zhiburtovich YY, Lyakhov AS et al. Radical oxidation of 17-functionalized 14 α -hydroxy steroids. *Collect Czech Chem Commun* 2001;66:1764–76.
- [15] Thacker JD, Bordner J, Bumgardner C. Carolinoside: a phytosteroidal glycoside from *Solarium carolinense*. *Phytochemistry* 1990;29:2965–70.
- [16] Kirson I, Zaretskii VI. Withaphysalin C, a naturally occurring 13,14-seco-steroid, *J Chem Soc Perkin Trans* 1976;(I):1244–7.
- [17] Ahmed B, Rahman A. Bacosterol, a new 13,14-seco-steroid and bacosine, a new triterpene from *Bacopa monniera*. *Indian J Chem* 2000;39B:620–5.
- [18] Altomare A, Burla MC, Camalli M, Cascarano G, Giacovazzo C, Guagliardi A, et al. SIR97: a new tool for crystal structure determination and refinement. *J Appl Cryst* 1999;32:115–9.
- [19] Sheldrick GM. Program for Crystal Structure Refinement, University of Goettingen, 1997.
- [20] Timms GH, Wildsmith E. The reduction of oximes with trivalent titanium, a mild deoximation procedure and the partial synthesis of erythromycylamine. *Tetrahedron Lett* 1971;2:195–8.
- [21] Corey EJ, Richman JE. Reaction of oxime *O*-acetates with chromous acetate. A method for the conversion of ketoximes to ketones under mild conditions. *J Am Chem Soc* 1970;92:5276–7.
- [22] Farrugia LJ. Ortep-3 for Windows. *J Appl Cryst* 1997;30:565.